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The Inhaled Steroids in Obstructive Lung Disease (ISOLDE) study was a trial that randomised
752 patients with moderate to severe COPD to fluticasone propionate 1000 mcg/day or placebo
for three years.
We aimed to examine the causes of death of the ISOLDE participants after the original three
up to 13 years post-randomisation. Death certificates were obtained either from the NHS Stra-
tegic Tracing Service or from the Office of National statistics. Deaths were classified according
to the trial protocol.
In the subsample of 375 participants from the seven ISOLDE original centers where complete
extended follow-up was conducted, the factors associated with observed higher mortality
(p< 0.05) were male gender, older age and more severe COPD. Causes of death were; 107
(52%) respiratory, 38 (18%) cardiac, 29 (14%) lung cancer, 16 (8%) other cancer and 16 (8%)
other causes. The percentage of respiratory-related deaths increased during the follow-up pe-
riod; from 46% within the three-year trial, to 48% after 3e6 years, 57% after 6e9 years, and 60%
after 9e13 years of follow-up (p for trend< 0.05).
We conclude that participants’ survival is poor (only 44% in the 13 years after the ISOLDE
trial), and that respiratory-related illnesses were the most frequent causes of death in patients
with moderate to severe COPD.
ª 2008 Elsevier Ltd. All rights reserved.Epidemiology and Clinical Research, CIMERA, Recinte Hospital Joan March, Carretera Soller Km 12,
4 84 37; fax: þ34 971 14 84 42.
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soriano@caubet-cimera.es (J.B. Soriano).
8 Elsevier Ltd. All rights reserved.
Long-term mortality follow-up of the ISOLDE particip ants 1469Introduction
Chronic obstructive pulmonary disease (COPD) represents
an important and increasing burden throughout the world.
This burden is expected to increase for the foreseeable
future.1
COPD is currently considered a preventable, treatable
disease in international guidelines.2,3 Efforts to understand
the natural history and all events related to COPD, includ-
ing death, are to be considered as a research priority.4
This includes initial triggers to last circumstances.
The Global Burden of Disease Study from the World
Health Organization (WHO) has been systematically assess-
ing worldwide statistics on specific causes of death and
disability since 1990.5 According to the WHO, at least 2.9
million deaths are due to COPD every year. Their 30-year
projections for the global increase in COPD are startling.6
Of all of the descriptive epidemiological data available for
COPD, mortality data are the most readily accessible.
However, this data has to be interpreted with caution. As
a ballpark figure, mortality rates due to COPD are 50 per
100,000 in males and 20 per 100,000 in females. The striking
increase in COPD as a cause of death is projected to occur
because of the worldwide prevalence of smoking and
changing global demographics. More people in developing
countries are living longer and are, therefore, at risk of
COPD for longer periods.7 Although COPD mortality is com-
mon and will become evenmore frequent, there is a relative
scarcity of data on the causes and circumstances of death in
COPD patients.8,9
The Inhaled Steroids in Obstructive Lung Disease
(ISOLDE) study10 was a trial that randomised 752 patients
with moderate to severe COPD to fluticasone propionate
(FP) 1000 mcg/day or placebo for three years. The first
mortality assessment of ISOLDE looked at causes of death
in all patients at three years post-randomisation. This
showed a marginal survival advantage in the FP group
(pZ 0.057).11 Four percent of randomised patients had
died within the first three years. The aim of this study is
to examine the specific causes of death of the ISOLDE par-
ticipants between 3 and 13 years post-randomisation.Methods
Summary of ISOLDE methods
It included the group was aged between 40e75 years and
had non-asthmatic chronic obstructive pulmonary disease.
Seven hundred and fifty two patients with a mean forced
expiratory volume in one second (FEV1) lower than 50% of
the predicted normal were recruited from 18 hospitals in
the UK. The original aim was to determine the effect of
FP on lung function, exacerbations, and health status. Af-
ter the three years of randomised treatment, subsequent
treatment was resumed by the treating physician. As the
randomisation code was unbroken for 1e3 years after trial
completion, subsequent management was unlikely to have
been influenced by treatment taken during the rando-
mised period. We have no complete information on drugs
taken or smoking after the first three years.The original ISOLDE study was approved by 18 in-
dependent local ethics committees whose authority had
been superseded by multi-center research ethics commit-
tees (MREC) before the current mortality study was
started. Seven of 18 local ethics committees approved
this study; the others required approval from MRECs, who
declined as they had not approved the original protocol.
The current study reports all ISOLDE patients up to three
years post-randomisation and patients from the seven
ISOLDE centers with ethics approval up to 13 years post-
randomisation.
Ascertainment of death
Life status was confirmed by the NHS Strategic Tracing
Service. Data on known deaths were checked against the
NHS central registers to assess accuracy. Death certificates
were obtained from the Office of National Statistics. Two
investigators independently reviewed all death certificates
and grouped the primary (underlying) cause of death into
five categories: respiratory, cardiac, lung cancer, other
cancer and all other causes. Both assessors were blinded to
treatment allocated during the trial.
Statistical methods
Survival was compared using standard KaplaneMeier statis-
tics. The following groups were analyzed separately: pa-
tients randomised to FP or placebo in the first three years,
confirmed non-smokers during randomised treatment, con-
tinuing and intermittent smokers, males, females and
participants with mild, moderate or severe COPD at
randomisation. Comparison of groups was with analysis of
variance for continuous variables and Chi square for
categorical variables. A p value lower than 0.05 was consid-
ered statistically significant.
Results
Baseline characteristics of the 375 participants in the seven
centers which completed extended follow-up were similar
to the 366 participants of the 11 centers not surveyed
(Table 1). The statistical differences in FEV1 and weight
should be considered clinically irrelevant.
Baseline BMI (Table 2) was the only difference in any of
the demographic and clinical characteristics considered
among the ISOLDE participants who were randomised to
FP or placebo and followed up in this study. A total of 209
deaths (56%) were observed out of the 375 participants in
these seven centers after 13 years of follow-up. Death cer-
tificates were obtained for 206 (98 %) participants. There
were no differences in total mortality among the ISOLDE
participants randomised to FP or placebo (Fig. 1). Male gen-
der, older age, and more severe COPD at baseline were as-
sociated with observed higher mortality (p< 0.05), but
there were no differences according to baseline smoking
status (Fig. 2). Other variables like body mass index and
pack-years were not associated with mortality. Regretta-
bly, other potentially important baseline characteristics
like cardiovascular comorbidity or socioeconomic status
were not collected in a standardised way at baseline.
Table 1 Baseline characteristics of randomised participants from centers in Group 1: without ethics consent; Group 2; with
ethics consent
Group 1
(nZ 366, 49.4%)
Group 2
(nZ 375, 50.6%)
p-Value
Age, yrs. 64.5 7.5 64.5 6.7 0.898
Male, n (%) 275 (75.1) 280 (74.7) 0.450
Smoker status, n (%)
(ex/mixed/current), n (%)
168 (45.9) 176 (46.9) 0.915
57 (15.6) 61 (16.3)
141 (38.5) 138 (36.8)
Pack-yrs of smoking 41.9 30.3 45.9 33.2 0.084
FEV1, l. 1.48 0.5 1.35 0.4 0.000
Weight, kg. 73.4 15.7 69.8 14.4 0.001
Height, cm. 170.3 8.6 169.6 7.9 0.241
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38 (18%) cardiac, 29 (14%) lung cancer, 16 (8%) other cancer
and 16 (8%) other causes. There were no differences in spe-
cific causes of death among the ISOLDE participants rando-
mised to FP or placebo (data not shown).
The percentage of respiratory-related deaths increased
with longer follow-up from 46% within the three-year trial,
48% after 3e6 years, 57% after 6e9 years and to 60% after
9e13 years of follow-up (p for trend< 0.05) (Fig. 3).
Death certificates mentioning pneumonia or broncho-
pneumonia as a cause of death during the three year
randomised treatment period were compared between
the FP and placebo arms for all centers and participants
(nZ 751). There were three deaths from pneumonia and 10
from bronchopneumonia in the placebo group and one
death from pneumonia and four from bronchopneumonia
in the FP arm (p not significant). Post-randomisation, there
were 10 in placebo and four in FP in the subsample
analyzed.
Discussion
By following up ISOLDE participants up to 13 years after
randomisation, this study confirms that COPD is associatedTable 2 Baseline characteristics of ISOLDE participants who we
(nZ 375)
Age in years, mean (SD)
Women, n (%)
Body mass index in kg/m2, mean (SD)
Smoking pack-years at randomisation, mean (SD)
Baseline PBD FEV1 in ml, mean (SD)
% predicted baseline PBD FEV1, mean (SD)
Deaths during 0e3 years
Deaths during 0 e13 years
a p-value< 0.05.with high lethality and that respiratory-related illnesses
were the most frequent causes of death in these moderate
to severe COPD patients. Some limitations are worth
considering. As previously stated, there was incomplete
access to data from all centers; however, the seven
participating centers should have no major bias. There
are some limitations when using death certificate data.
Since this was a 13-year assessment, there is an absence of
information on both smoking after the baseline assessment
and of switchers of respiratory medications after trial
completion.
Some strengths of the study include near complete
availability of death certificates, and consistency with a pri-
ori knowledge of death by age, gender and COPD severity.
These results compare well with some recent extended fol-
low-up studies after trial completion in COPD, mirroring ex-
amples in cardiovascular and cancer trials. The Lung Health
Study researchers (LHS)12 reported in 2005, an extension of
the initial trial assessment of deaths after a 14-year follow-
up.13 From this original sample of mild COPD participants,
731 patients died: 33% of lung cancer, 22% of cardiovascular
disease, 7.8% of respiratory disease other than cancer, and
2.3% of unknown causes. There were differences in mortal-
ity in the LHS usual care group compared with the smokingre followed up beyond the three years of the trial duration
FP (nZ 185) Placebo (nZ 190)
64.4 (6.4) 64.5 (6.9)
42 (22.7) 53 (27.9)
23.7 (4.2)a 24.6 (4.7)
47.0 (32.0) 44.8 (34.4)
1.35 (0.4) 1.34 (0.4)
47.7 (14.0) 48.5 (14.6)
30 dead (16.2%) 34 dead (17.9%)
155 alive 156 alive
103 dead (55.7%) 106 dead (55.8%)
82 alive 84 alive
Figure 1 KaplaneMeier survival curves of individuals with
complete long-term follow-up randomised to FP or placebo.
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cardiovascular disease were greater when rates were ana-
lyzed by smoking habit.
Reanalysis of old trial data can generate new hypothe-
ses. For example, investigators from the EuropeanFigure 2 KaplaneMeier survival curves of ISOLDE participants
according to gender, age [10-year bands], smoking, and severity oRespiratory Society Study on Chronic Obstructive Pulmo-
nary Disease (EUROSCOP)14 also recently reported the
mortality results of this study, supporting the hypothesis
that treatment with inhaled corticos teroids tends to re-
duce ischaemic cardiac events in patients with mild
COPD.15
The largest and most comprehensive assessment of
COPD deaths completed to date is from the TOwards
a Revolution in COPD Health (TORCH) trial.16 Overall, 911
deaths were reviewed and a final consensus on the specific
cause/s of death was reached for each.17 The TORCH inclu-
sion criteria for COPD severity were very similar to the
ISOLDE inclusion criteria The proportions were; respiratory
35%, cardiovascular 27%, cancer 21%, other 10% and
unknown 8%. There were, therefore, strong similarities
between the ISOLDE study and the TORCH results in which
40% of deaths were definitely or probably related to
COPD.18 Interestingly, there were less reports of pneumonia
and bronchopneumonia in the ISOLDE participants rando-
mised to FP than to placebo during the ISOLDE trial, or after
trial completion up to 13 years of follow-up.
A methodological issue of potential interest to other
researchers when conducting extended follow-ups of com-
pleted trials is the variable and inconsistent response from
MRCEs. Regrettably, within our study the MRCEs of 11 out of
the 18 original ISOLDE participating centers did not grant
permission to search for survival/mortality data after trialwith complete long-term follow-up (clockwise from top left)
f COPD (composite).
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Figure 3 Cause of death by year interval of ISOLDE partici-
pants with complete long-term follow-up.
1472 G. Bale et al.completion. This limitation has been identified by others
elsewhere.19,20 A fine balance between protection of par-
ticipants and community knowledge should be searched
when assessing each study proposal by MRCEs.
We conclude that survival of ISOLDE participants is poor
(44%) 13 years after the trial completion, and that re-
spiratory-related deaths were the most frequent causes of
death in these moderate to severe COPD patients.
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